MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy

Juyong Yoon, Kyoung Hwa Koo, Kang Yell Choi

Research output: Contribution to journalArticlepeer-review

75 Citations (Scopus)

Fingerprint

Dive into the research topics of 'MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy'. Together they form a unique fingerprint.

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Agricultural and Biological Sciences